Elocta
efmoroctocog alfa · Swedish Orphan Biovitrum AB (publ)
AUTHORISED IN THE EUWhat Elocta is used for
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Elocta can be used for all age groups.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Elocta
- Active substance
- efmoroctocog alfa
- Disease area
- Hemophilia A
- Medicine group
- Antihemorrhagics
- ATC code
- B02BD02
- Marketing authorisation holder
- Swedish Orphan Biovitrum AB (publ)
- Authorised in the EU since
- 2015
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elocta used for?
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Elocta can be used for all age groups.
What is the active substance in Elocta?
Elocta contains efmoroctocog alfa.
Who makes Elocta?
The EU marketing authorisation holder is Swedish Orphan Biovitrum AB (publ).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU